Outpatient management of community-acquired pneumonia

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

PURPOSE OF REVIEW: Although most patients with community-acquired pneumonia (CAP) are treated as outpatients, the majority of data regarding CAP management is provided by hospitals, either from emergency department or inpatients. This was already noted in the first CAP guidelines, published in 1993, and the challenges regarding the outpatient management of CAP persist nowadays. These include the uncertainty of the initial diagnosis and risk stratification, the empirical choice of antibiotics, the overgrowing of antibiotic resistance bacteria and the relative scarcity of novel antibiotics. RECENT FINDINGS: New molecular biology methods have changed the etiologic perspective of CAP, unveiling the role of virus. Diagnostic uncertainty may lead to antibiotic overuse and bacteria resistance. Novel antibiotics along with diagnostic improvement, related to the use of lung ultrasound and point-of-care biomarkers testing, may help to improve CAP treatment. Prevention, especially the use of antipneumococcal vaccine, is instrumental in reducing the burden of disease. SUMMARY: Most of CAP cases are managed in the outpatient setting. However, most research is focused on hospitalized severe patients. New and awaited advances might contribute to aid diagnosis, cause and assessment of patients with CAP in the community. This knowledge might prove decisive in improving outcomes, as well as to the execution of stewardship programs that maintain current antibiotics, safeguard future ones and reinforce prevention.

Original languageEnglish
Pages (from-to)249-256
Number of pages8
JournalCurrent opinion in pulmonary medicine
Volume25
Issue number3
DOIs
Publication statusPublished - 1 May 2019

Fingerprint

Pneumonia
Outpatients
Anti-Bacterial Agents
Uncertainty
Bacteria
Microbial Drug Resistance
Hospital Emergency Service
Inpatients
Molecular Biology
Vaccines
Biomarkers
Guidelines
Viruses
Lung
Research

Cite this

@article{084c52e403f346d58869781674d6df25,
title = "Outpatient management of community-acquired pneumonia",
abstract = "PURPOSE OF REVIEW: Although most patients with community-acquired pneumonia (CAP) are treated as outpatients, the majority of data regarding CAP management is provided by hospitals, either from emergency department or inpatients. This was already noted in the first CAP guidelines, published in 1993, and the challenges regarding the outpatient management of CAP persist nowadays. These include the uncertainty of the initial diagnosis and risk stratification, the empirical choice of antibiotics, the overgrowing of antibiotic resistance bacteria and the relative scarcity of novel antibiotics. RECENT FINDINGS: New molecular biology methods have changed the etiologic perspective of CAP, unveiling the role of virus. Diagnostic uncertainty may lead to antibiotic overuse and bacteria resistance. Novel antibiotics along with diagnostic improvement, related to the use of lung ultrasound and point-of-care biomarkers testing, may help to improve CAP treatment. Prevention, especially the use of antipneumococcal vaccine, is instrumental in reducing the burden of disease. SUMMARY: Most of CAP cases are managed in the outpatient setting. However, most research is focused on hospitalized severe patients. New and awaited advances might contribute to aid diagnosis, cause and assessment of patients with CAP in the community. This knowledge might prove decisive in improving outcomes, as well as to the execution of stewardship programs that maintain current antibiotics, safeguard future ones and reinforce prevention.",
author = "Filipe Froes and Pereira, {Jo{\~a}o Gon{\cc}alves} and Pedro P{\'o}voa",
year = "2019",
month = "5",
day = "1",
doi = "10.1097/MCP.0000000000000558",
language = "English",
volume = "25",
pages = "249--256",
journal = "Current opinion in pulmonary medicine",
issn = "1070-5287",
publisher = "Lippincott, Williams & Wilkins",
number = "3",

}

Outpatient management of community-acquired pneumonia. / Froes, Filipe; Pereira, João Gonçalves; Póvoa, Pedro.

In: Current opinion in pulmonary medicine, Vol. 25, No. 3, 01.05.2019, p. 249-256.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Outpatient management of community-acquired pneumonia

AU - Froes, Filipe

AU - Pereira, João Gonçalves

AU - Póvoa, Pedro

PY - 2019/5/1

Y1 - 2019/5/1

N2 - PURPOSE OF REVIEW: Although most patients with community-acquired pneumonia (CAP) are treated as outpatients, the majority of data regarding CAP management is provided by hospitals, either from emergency department or inpatients. This was already noted in the first CAP guidelines, published in 1993, and the challenges regarding the outpatient management of CAP persist nowadays. These include the uncertainty of the initial diagnosis and risk stratification, the empirical choice of antibiotics, the overgrowing of antibiotic resistance bacteria and the relative scarcity of novel antibiotics. RECENT FINDINGS: New molecular biology methods have changed the etiologic perspective of CAP, unveiling the role of virus. Diagnostic uncertainty may lead to antibiotic overuse and bacteria resistance. Novel antibiotics along with diagnostic improvement, related to the use of lung ultrasound and point-of-care biomarkers testing, may help to improve CAP treatment. Prevention, especially the use of antipneumococcal vaccine, is instrumental in reducing the burden of disease. SUMMARY: Most of CAP cases are managed in the outpatient setting. However, most research is focused on hospitalized severe patients. New and awaited advances might contribute to aid diagnosis, cause and assessment of patients with CAP in the community. This knowledge might prove decisive in improving outcomes, as well as to the execution of stewardship programs that maintain current antibiotics, safeguard future ones and reinforce prevention.

AB - PURPOSE OF REVIEW: Although most patients with community-acquired pneumonia (CAP) are treated as outpatients, the majority of data regarding CAP management is provided by hospitals, either from emergency department or inpatients. This was already noted in the first CAP guidelines, published in 1993, and the challenges regarding the outpatient management of CAP persist nowadays. These include the uncertainty of the initial diagnosis and risk stratification, the empirical choice of antibiotics, the overgrowing of antibiotic resistance bacteria and the relative scarcity of novel antibiotics. RECENT FINDINGS: New molecular biology methods have changed the etiologic perspective of CAP, unveiling the role of virus. Diagnostic uncertainty may lead to antibiotic overuse and bacteria resistance. Novel antibiotics along with diagnostic improvement, related to the use of lung ultrasound and point-of-care biomarkers testing, may help to improve CAP treatment. Prevention, especially the use of antipneumococcal vaccine, is instrumental in reducing the burden of disease. SUMMARY: Most of CAP cases are managed in the outpatient setting. However, most research is focused on hospitalized severe patients. New and awaited advances might contribute to aid diagnosis, cause and assessment of patients with CAP in the community. This knowledge might prove decisive in improving outcomes, as well as to the execution of stewardship programs that maintain current antibiotics, safeguard future ones and reinforce prevention.

UR - http://www.scopus.com/inward/record.url?scp=85063968136&partnerID=8YFLogxK

U2 - 10.1097/MCP.0000000000000558

DO - 10.1097/MCP.0000000000000558

M3 - Article

VL - 25

SP - 249

EP - 256

JO - Current opinion in pulmonary medicine

JF - Current opinion in pulmonary medicine

SN - 1070-5287

IS - 3

ER -